Good day, and welcome to the Tango Therapeutics conference call. [Operator Instructions] Please note, this call is being recorded. I'd now like to turn the call over to Liz Hickin, Vice President, ...

A shift in the way people think about and treat pancreatic cancer could be on the horizon based on positive results from the pivotal randomized phase 3 RASolute 302 trial comparing daraxonrasib to ...

Tri-complex inhibitors (TCIs) are molecular glues that bind to active GTP-bound RAS and recruit the intracellular chaperone cyclophilin A (CYPA) to generate a synthetic inhibitory complex that blocks ...

Dean Fioresi is a web producer for CBS Los Angeles. He covers breaking news throughout Southern California. When he's not writing about local events, he enjoys focusing on sports and entertainment.

- The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program - - 30 mg onvansertib + ...

Voters in six states have primaries today. Election officials predict that results will come in late Tuesday or early Wednesday. By Taylor Robinson Six states are holding primary races on Tuesday, ...

Primary contests will be held in six states on Tuesday. We’ll be paying close attention to California, where dozens of candidates are vying to replace Gov. Gavin Newsom in an open primary. Here’s what ...

At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously ...

Texas voters are choosing party nominees in runoff elections for several key statewide, congressional and local races after no candidate won a majority in the March primary. The Republican ballot ...

The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated RAS-mutant metastatic pancreatic cancer, according to a Phase I/II ...